GenEdit is a rapidly growing, early-stage company that is developing a proprietary and novel delivery platform with the potential to transform genetic medicine. Our interdisciplinary team works together across chemistry, payload, formulation, screening, and preclinical groups to develop the next generation of gene therapies. GenEdit fosters an exciting and dynamic environment where we value impactful data and creative solutions to accelerate our progression from platform technology to a pipeline of therapeutic candidates. We are seeking talented and motivated individuals to join our team and are expanding across all functions within the organization. Join us in South San Francisco, CA, to be at the forefront of the future of gene therapy.
We are seeking a Director of Immunology to join our cross-functional discovery teams and create novel drug candidates.
Key Responsibilities
-Drive internal and external partnered research from new target identification and technology platform development to create therapeutic opportunities for patients with autoimmune and inflammatory diseases.
-Function as the key project leader of multi-functional scientific teams and ensure successful and timely execution of one or more preclinical research programs.
-Be a strong scientific thinker with considerable experience leading the discovery and development of therapies for immunological diseases.
-Lead the identification of novel innovative inflammation drug discovery and developmental science through the preclinical pipeline in support of candidate selection.
-Interface with senior leadership, alliance management, and the business development group and review innovative external opportunities.
-Be a highly collaborative and energetic scientist and leader with superior communication skills, who can balance multiple, collaborative projects and act as a senior scientific consultant to and leader of early-stage matrixed project teams.
Qualifications
-PhD degree in Immunology or a closely related discipline with 10+ years of experience
-6 years desired minimum industry experience
-2 years minimum management experience ideally as a research project leader focused on strategic external collaborations.
-Experience developing and evaluating novel nanoparticle or nucleic acid therapeutics for immune therapeutics is highly desirable.
-Desired technical skills:
· Highly knowledgeable and experienced in all aspects of drug discovery and development for Inflammatory or autoimmune diseases through proof of concept.
· Experienced with validation of drug targets and the exploratory drug development process with a proven track record.
· Extensive experience developing and/or evaluating novel small molecule, biologic or nucleic acid therapeutics.
· Excellent written and verbal communication skills in English.
-Desired behavioral competencies:
· Forward thinking with the ability to recommend, influence and implement organizational change and continuous innovation.
· Ability to build strong relationships and collaborate effectively with other interfacing GenEdit functions.
·Comfortable challenging the status quo and bringing forward innovative solutions.
·Ability to take risks implementing innovative solutions.
·Proven skills as an effective team player who can engender credibility and confidence within and outside the company.
Top Skills
What We Do
GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.
The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease.
We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.